NTI's Principal Activity is the neurotech researches, designs, markets and through third party manufacturers, produces wearable neurotechnology devices to assist with neurological conditions such as autism.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+458.82%|
|vs ASX 200 (1yr)||+445.34%|
|ASX Rank||1,460 of 2,295|
|Sector Rank||130 of 177|
Neurotech International Limited (NTI) is a medical device and solutions company whose primary mission is to improve the lives of people with neurological conditions. NTI operates in one segment being Medical Device Development and Distribution. The Company incorporated in Australia, operating through its wholly-Owned, malta-based subsidiary, AAT Research Limited.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Professor Allan Cripps||Non-Executive Director||May 2021||
Professor Allan Cripps
Prof Cripps is currently a Professor Emeritus in the School of Medicine and Dentistry and the Menzies Health Institute Queensland at Griffith University, Australia. He is a member of the Infection and Immunity Research Team at the Menzies Health Institute Queensland at Griffith University, Australia. He has gained experience working as a clinical scientist, academic and health services executive and has made contributions in immunology, vaccine development, diagnostics health services delivery and professional health education. Prof Cripps has experience in the development of immunity in children and mucosal immune mechanisms, in recent years he has contributed to the field of immunology through translational research and human clinical studies. Prof Cripps is also a co-inventor on several patents in the fields of diagnostic technology and vaccine protein antigens for respiratory infection. He has published over 325 peer-reviewed scientific papers and presented them at many national and international scientific conferences. In 2012 he launched the first international peer-reviewed journal focused on pneumonia as a means for bringing together knowledge related to pathogenesis, treatment and prevention of this disease and remains the Journals Founding Editor. Prof Cripps is a member of the journal VACCINE Council of 100. This Council is made up of 100 of the world's vaccine researchers and clinicians and provides advice on vaccine development to both the Journal and other organisations globally. He is also a member of the Immunisation Coalition and a member of the Coalition's Scientific Advisory Committee and is currently appointed to industry advisory boards for advice on strategies related to the development of vaccines for respiratory infections in children and adults including those with chronic lung conditions.
|Ms Krista Bates||Non-Executive Director||Apr 2021||
Ms Krista Bates
Ms Bates is an experienced non-executive and executive director of listed companies (Australian Stock Exchange and London Stock Exchange) and various private companies in multiple jurisdictions. She has a legal background with over 20 years' experience in the legal market, with experience working in emerging markets in both a commercial and legal capacity. Ms Bates is currently a Non-executive Director of AusCann Holdings (ASX:AC8) and Australia-Africa Minerals & Energy Group. She is also a Corporate Partner at Lavan law firm, where she is Head of Mining & Resources Group and Head of Medical Cannabis Group. Formerly, she has held both Executive and Non-executive Directorship roles at Credit Intelligence (ASX:CI1) and Fastjet, London, Nairobi, Harare and Dar es Salaam (LSE:FJET), and has held Corporate Partner roles at Anjarwalla & Khanna (Nairobi, Kenya) and Clyde & Co (London and Dar es Salaam, Tanzania).
|Mr Brian Willoughby Leedman||Non-Executive Chairman,Non-Executive Director||Oct 2020||
Mr Brian Willoughby Leedman
Non-Executive Chairman,Non-Executive Director
Mr Leedman has over 15 years' experience in the biotechnology sector. Mr Leedman is formerly the Chairman (WA) of Ausbiotech, Founder and Executive Director of ResApp Health, Founder of Oncosil Medical and Biolife Sciences Limited (acquired by Imugene Limited) and Nonexecutive Director of Alcidion Corporation. He is presently the Chairman or NeuroScientific Biopharmaceuticals and Chairman of Nutritional Growth Solutions.
|Mr Winton William Willesee||Non-Executive Director||Apr 2019||
Mr Winton William Willesee
Mr Willesee is an experienced corporate professional with a range of skills and experience strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance. Mr Willesee has experience with ASX listed and other companies over a range of industries, having held directorships, chairmanships and company secretarial positions with a number of ASX-listed companies over many years.
|Mr Mark Davies||Non-Executive Director||Apr 2019||
Mr Mark Davies
Mr Davies has over 20 years experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.
|Ms Erlyn Dale||Company Secretary||Apr 2019|
NTI directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|14/07/21||Allan Cripps||Buy||+180,000||$0.056||$10,017||On-market trade|
|14/07/21||Krista Bates||Buy||+180,000||$0.056||$10,044||On-market trade|
|22/06/21||Brian Leedman||Buy||+933,589||$0.054||$49,961||On-market trade|
|13/04/21||Krista Bates||Buy||+270,000||$0.074||$19,980||On-market trade|
|17/12/20||Winton Willesee||Issued||2,000,000||$0.056||$112,000||Issue of options|
|17/12/20||Mark Davies||Issued||2,000,000||$0.056||$112,000||Issue of options|
|17/12/20||Brian Leedman||Issued||20,000,000||$0.056||$1,120,000||Issue of options|
|05/10/20||Winton Willesee||Transfer||1,252,852||$0.013||$16,287||Off-market transfer|
|05/10/20||Winton Willesee||Issued||6,047,382||$0.008||$48,500||Director remuneration|
|30/09/20||Peter Griffiths||Issued||16,957,606||$0.008||$136,000||Director remuneration|
|30/09/20||David Cantor||Issued||4,551,122||$0.008||$36,499||Director remuneration|
|30/09/20||Mark Davies||Issued||7,793,017||$0.008||$62,499||Director remuneration|
|18/11/19||David Cantor||Buy||+2,000,000||$0.014||$28,000||As advised by the company|
|18/11/19||Mark Davies||Buy||+2,000,000||$0.014||$28,000||As advised by the company|
|18/11/19||Winton Willesee||Buy||+2,000,000||$0.014||$28,000||As advised by the company|
|18/11/19||Peter Griffiths||Buy||+11,929,754||$0.014||$167,017||As advised by the company|
|25/02/19||Peter O'Connor||Issued||503,100||$0.026||$13,081||Rights issue|
|25/02/19||Peter Griffiths||Issued||2,634,790||$0.03||$79,044||Rights issue|
|25/02/19||Simon Trevisan||Issued||3,333,334||$0.03||$100,000||Rights issue|
|25/02/19||Peter Griffiths||Issued||2,634,790||$0.026||$68,505||Rights issue|
|25/02/19||Peter O'Connor||Issued||503,100||$0.03||$15,093||Rights issue|
|25/02/19||Simon Trevisan||Issued||3,333,334||$0.026||$86,667||Rights issue|
|04/12/18||David Cantor||Issued||142,857||$0.14||$20,000||Issue of securities|
The current holdings of NTI directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Shimano Ventures Limited||30/09/2020||24,249,984||6.24|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|30-09-20||Shimano Ventures Limited||24,249,984||--||6.24|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|12-11-20||J and J Bandy Nominees Pty Ltd||23,344,887||10.85||--|
|12-11-20||Jalaver Pty Ltd||22,645,178||10.52||--|
|07-09-20||Bonvoyolo Pty Ltd||12,596,786||5.85||--|
|30-07-20||Stephen J Dobson||15,096,786||7.01||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.